Long-Term Follow-up Protocol for Subjects Treated With JCAR015

Trial Profile

Long-Term Follow-up Protocol for Subjects Treated With JCAR015

Discontinued
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs JCAR 015 (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Juno Therapeutics
  • Most Recent Events

    • 09 Oct 2017 Planned End Date changed from 1 Dec 2036 to 1 Dec 2032.
    • 09 Oct 2017 Planned primary completion date changed from 1 Dec 2036 to 1 Dec 2032.
    • 01 Mar 2017 According to a Juno Therapeutics media release, the company has made a strategic decision to cease development of JCAR015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top